Adaptimmune's second T cell receptor cell therapy for rare sarcomas passes pivotal test

Adaptimmune announced Wednesday that its experimental cell therapy based on T cell receptors shrank tumors by at least 30% in nearly half of the patients in a pivotal clinical trial. In 64 patients with previously ...